Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 1/2 1

Status

Completed 22Terminated 5Active not recruiting 3Withdrawn 2Suspended 1Recruiting 1No longer available 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2

Conditions

Lymphoma, T-Cell 2Lymphoma, Large-Cell, Anaplastic 2Lymphoma 2Hematologic Neoplasms 2Subcutaneous panniculitis-like T-cell lymphoma 1Sezary Syndrome 1Recurrence 1Mycosis Fungoides 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, Non-Hodgkin 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Leukemia, Lymphocytic, Chronic, B-Cell 1Infectious Mononucleosis 1Immunoblastic Lymphadenopathy 1Hodgkin Disease 1Enteropathy-Associated T-Cell Lymphoma 1

Interventions

Rituximab 20Cyclophosphamide 18Etoposide 11Vincristine 10Doxorubicin 10fludarabine phosphate 9Prednisone 9Filgrastim 9Radiotherapy 8Peripheral Blood Stem Cell Transplantation 8Cytarabine 8Methotrexate 7Melphalan 7Dexamethasone 6fludarabine 4Cyclosporine 4Antilymphocyte Serum 4duvelisib 3belinostat 3Thiotepa 3Tacrolimus 3Nivolumab 3Mycophenolic Acid 3Lenalidomide 3Ifosfamide 3Gemcitabine 3Carmustine 3Busulfan 3Alemtuzumab 3sargramostim 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Withdrawn × Lymphoma × Brentuximab Vedotin × Clear all
NCT02408042 2017-06-27

Study of Pembrolizumab With Chemotherapy in Patients With Advanced Lymphoma (PembroHeme)

Western Regional Medical Center

Phase 1/2 Withdrawn
Lymphoid

Hodgkin Disease, Lymphoma, Lymphoma, Non-Hodgkin

NCT01671813 2013-07-25

Brentuximab Vedotin in CD30 Positive Epstein Barr Virus (EBV) Positive DLBCL of Elderly

H. Lee Moffitt Cancer Center and Research Institute

Phase NA Withdrawn
Lymphoid

Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡